Donate

FDA Accepts CSL Behring’s Application for New Hemophilia Treatment

July 28, 2015

Note: The below is an edited press release from CSL Behring. To read the full release, click here. CSL Behring announced that the U.S. Food and Drug Administration has accepted for review the company’s Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In the […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.